All In Biotech

NDA 206977 · Ibsa

Tirosint-Sol

Levothyroxine Sodium · Oral

Last checked: Nov 21, 2026Latest source record: Nov 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Dec 15, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

216

36 Phase 3, 17 recruiting

FAERS reports

105,950

71,861 serious, 8,452 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including TIROSINT-SOL, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning Thyroid hormones, including TIROSINT-SOL, should not be used for the treatment of obesity or for weight loss. Doses beyond the range of daily hormonal requirements may produce...

What it is approved for

From the label in effect Mar 27, 2026.

1 INDICATION AND USAGE TIROSINT-SOL is L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer ( 1 ) Limitations of Use Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients ( 1 ) Not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis ( 1 ) Hypothyroidism TIROSINT-SOL is indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression TIROSINT-SOL is indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use Tirosint-SOL is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with TIROSINT-SOL may induce hyperthyroidism [see Warnings and Precautions (5.1) ] . Tirosint-SOL is not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis.

Mechanism: Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

15 products under this application
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 137MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 62.5MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 112MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 37.5MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 88MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 175MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 50MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 13MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 125MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 44MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 100MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 200MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 75MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 150MCG/ML · SOLUTION, ORAL · Prescription
  • TIROSINT-SOL · LEVOTHYROXINE SODIUM 25MCG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levothyroxine" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue8,794
  • nausea7,563
  • diarrhoea6,822
  • headache6,722
  • dyspnoea6,540
  • drug ineffective5,752
  • pain5,521
  • dizziness5,325
  • vomiting4,644
  • asthenia4,534
  • malaise4,354
  • off label use4,266

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,043
20052,018
20062,180
20072,761
20084,015
20093,824
20104,310
20116,158
20126,850
20131,453
20141,810
20152,608
20163,443
20173,901
20184,524
20194,399
20205,903
20216,176
20227,733
20237,405
20247,735
20258,648
20266,052

Recalls

15 FDA enforcement reports for this application.

  • Jan 30, 2023 · Class II · Terminated

    Subpotent Drug

  • Jan 30, 2023 · Class II · Terminated

    Subpotent Drug

  • Jan 30, 2023 · Class II · Terminated

    Subpotent Drug

  • Jan 30, 2023 · Class II · Terminated

    Subpotent Drug

  • Jan 30, 2023 · Class II · Terminated

    Subpotent Drug

  • Jan 30, 2023 · Class II · Terminated

    Subpotent Drug

  • Jan 30, 2023 · Class II · Terminated

    Subpotent Drug

  • Jan 30, 2023 · Class II · Terminated

    Subpotent Drug

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tirosint-Sol (Levothyroxine Sodium)

2024 spending

$2.6M

Beneficiaries

2,457

11,238 claims

Per beneficiary

$1,059

$4.63 per unit

View as table
YearSpending
2020$974,450
2021$1,491,858
2022$1,997,718
2023$1,876,820
2024$2,602,064

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 611 on PubMed

Sponsor: Ibsa

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.